You are here: Home Newsroom News No7 reveals its biggest ever scientific innovation with the launch of No7 Future Renew

No7 reveals its biggest ever scientific innovation with the launch of No7 Future Renew

10 April 2023
News Beauty

Created following 15 years of research into skin ageing and repair with the University of Manchester, No7 Future Renew contains a world-first super-peptide blend proven to harness the skin’s natural repair process.

No7, the UK’s number one skincare brand1, today announces the launch of No7 Future Renew; a collection of four skincare products proven to reverse the appearance of multiple signs of skin damage. The range contains a new ‘super peptide’ blend that is proven to harness the skin’s natural repair process and the renewal of over 50 key proteins in skin cells. The super peptide blend – which represents the biggest cosmetic science innovation in No7’s history – contains two brand-new chemical entities, a patent-pending world-first technology that cannot be found in any other product. 

No7 Future Renew and its super-peptide blend have been developed following 15 years of research and innovation using scientific methods and approaches that are more akin to medical research and rarely seen in cosmetic product development. The new peptide blend was developed using cutting edge British R&D across several fields of science and technology including advanced robotics, mathematical modelling, bioinformatics, machine learning, cell biology and cosmetic science.  

No7’s new super peptide is set to be one of the most effective and tolerated skincare ingredients on the cosmetic market. Unlike retinoic acid, which is known by dermatologists to cause tolerance challenges such as skin sensitivity and redness, No7's new super peptide is both highly potent and highly tolerated, being suitable even for those with sensitive skin. This paves the way to highly effective skincare being available to even more people. 

The No7 Future Renew range has undergone the most extensive and diverse testing programme in No7’s history - 37 studies on over 4,200 people, including two clinical trials and 23 user trials. More than half (51%) of the total testing group had skin of colour.  

At the heart of the collection is the No7 Future Renew Damage Reversal Serum, clinically proven in a blinded split-face controlled trial to reverse the appearance of multiple signs of skin damage across a range of skin types and tones, including fine lines, wrinkles, lack of luminosity, dryness, uneven skin tone and loss of firmness. 97% of women in the clinical study had improvements in the appearance of multiple (3 or more) visible signs of skin damage. Patent applications have been submitted and are pending for both the new peptides and the delivery system found within the serum.

No7’s Head of Science Research, Dr Mike Bell, said: “Skin damage happens throughout our lives and is caused by multiple factors including sun exposure, environmental pollution, stress, sleep, temperature and nutrition. The new peptide blend effectively tricks the skin into thinking that it has been damaged which leads to renewal of key proteins such as collagen and fibrillin. It therefore supports skin’s natural self-repair mechanisms, targeting signs of cumulative damage both on and under the surface. This is a world-first technology only available from No7. We believe it is going to be a game changer for consumers.” 

The new super peptide technology has been met with excitement from the global scientific community with the technology being presented at three world leading scientific conferences this Spring including the American Academy of Dermatology (AAD) Annual Conference in Louisiana, the British Society for Investigative Dermatology (BSID) Annual Meeting in Glasgow and the International Societies for Investigative Dermatology (ISID) meeting in Tokyo.  

Commenting on the launch of No7 Future Renew, Dr Emma Wedgeworth, consultant dermatologist, said: “I’m incredibly excited that No7 have discovered a new super-peptide blend that harnesses the skin’s natural repair process. No7 Future Renew is a breakthrough range that can help reverse visible signs of skin damage.  It contains a world-first peptide technology that you won’t find in any other skincare product.” 

The No7 Future Renew range will be available nationwide at Boots stores, and from 12 April 2023. Dermatologically approved, the range comprises:

No7 FUTURE RENEW DAMAGE REVERSAL SERUM 50ml - £42.95 / 25ml - £34.95

No7 Future Renew Serum is proven to reverse visible signs of skin damage in just four weeks. Visible signs of skin damage include the appearance of fine lines and wrinkles, uneven tone and texture, dry skin, and less elastic and firm feeling skin. 

It contains No7’s new super peptide blend, as well as niacinamide, hyaluronic acid, vitamin C, mulberry and hydrolysed rice proteins.


No7 Future Renew Day Cream is proven to protect against UV and reverse visible signs of skin damage, such as the feeling of dryness and loss of elasticity.​   It contains SPF40 for damage prevention, No7’s new super peptide blend, an antioxidant blend, niacinamide, hyaluronic acid, vitamin C and rice proteins.​ 

It intensely moisturises the skin for up to 72 hours, and within 1 week of use, users reported brighter, healthier, more supple skin.


No7 Future Renew Night Cream is expertly formulated to support skin's natural self-repair process while sleeping and reverse visible signs of skin damage.​ It contains the new super peptide blend, along with other key nourishing ingredients including shea butter, niacinamide and hyaluronic acid. ​​​

This night cream helps reverse the appearance of uneven tone and texture, dry skin and lost elasticity. It deeply moisturises for up to 72 hours, and delivers instant results with more nourished, softer and smoother skin. In as little as one week, users reported their skin felt supple and texture more even.


The skin around the eyes is thinner and more delicate than elsewhere on the face, meaning it is more susceptible to damage. Expertly developed for the delicate eye area, No7 Future Renew Eye Serum reverses visible signs of skin damage in 8 weeks.   ​

In addition to No7's super peptide blend, the eye serum also contains hyaluronic acid, niacinamide, vitamin C, an antioxidant blend and rice proteins.​ In one week, the appearance of fine lines is reduced, and after four weeks, the appearance of wrinkles and puffiness is reduced, and skin tone looks more even.



1 No7 reveals its biggest ever scientific innovation with the launch of No7 Future Renew.


What’s new at Boots? Find out the latest updates from the UK’s largest pharmacy-led health and beauty chain – from new products and services to important business developments.



Take a closer look at our team members and the work they do, learn more about our corporate social responsibility initiatives and see how we work behind the scenes.


Boots is the UK’s leading health and beauty retailer with over 52,000 team members and 2,100 stores, ranging from local community pharmacies to large destination health and beauty stores.*

Boots serves its customers and patients for life as the leading provider of healthcare on the high street and the UK’s number one beauty destination. It offers an unrivalled depth and breadth of products, which incorporates its extensive own brand range and innovative portfolio of brands, including No7, the UK’s No1 skincare brand, Soap & Glory, Liz Earle Beauty and Sleek MakeUP.

2024 marks Boots’ 175th anniversary year. Founder John Boot opened a herbalist store in Nottingham in 1849 to offer an affordable alternative to traditional medicines. His son Jesse expanded the business to become a modern retailer and the biggest chemist in Britain. Throughout its history, Boots has listened, learned and innovated, and it continues to challenge itself to improve its products and services every day.

Boots is part of Walgreens Boots Alliance, which is a global leader in pharmacy-led, health and wellbeing retail.  More company information is available on

*Figures accurate as of 30 November 2023